Q4 2024 13F Holders as of 12/31/2024
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
11.5M
-
Number of holders
-
37
-
Total 13F shares, excl. options
-
3.53M
-
Shares change
-
+149K
-
Total reported value, excl. options
-
$3.03M
-
Value change
-
+$128K
-
Put/Call ratio
-
0.06
-
Number of buys
-
8
-
Number of sells
-
-9
-
Price
-
$0.86
Significant Holders of TherapeuticsMD, Inc. - Common Stock, par value $0.001 per share (TXMD) as of Q4 2024
43 filings reported holding TXMD - TherapeuticsMD, Inc. - Common Stock, par value $0.001 per share as of Q4 2024.
TherapeuticsMD, Inc. - Common Stock, par value $0.001 per share (TXMD) has 37 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 3.53M shares
of 11.5M outstanding shares and own 30.55% of the company stock.
Largest 10 shareholders include Rubric Capital Management LP (1.19M shares), Clearline Capital LP (635K shares), Tejara Capital Ltd (395K shares), VANGUARD GROUP INC (388K shares), ADAR1 Capital Management, LLC (270K shares), CITADEL ADVISORS LLC (146K shares), MORGAN STANLEY (132K shares), BlackRock, Inc. (116K shares), GEODE CAPITAL MANAGEMENT, LLC (108K shares), and BRIDGEWAY CAPITAL MANAGEMENT, LLC (34K shares).
This table shows the top 37 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.